Oxford BioDynamics invited to join FNIH steering committee

Josh White Sharecast | 20 Apr, 2017 16:48 | | |

Astrazeneca

Oxford Biodynamics

128.50

17:17 28/04/17
1.18%
1.50
  • 963.72
  • 0.20%1.88
  • Max: 964.37
  • Min: 961.35
  • Volume: 0
  • MM 200 : n/a
17:20 28/04/17

Discovery and development of novel epigenetic biomarkers-focussed biotechnology company Oxford BioDynamics announced on Thursday that itself and Dr Claudio Carini, a member of company’s scientific advisory panel, had been invited to join the Foundation for the National Institutes of Health Biomarkers Consortium as a member of the Cancer, Inflammation & Immunity, and Neuroscience Steering Committees.

The AIM-traded firm said the Biomarkers Consortium is a public-private biomedical research partnership managed by the FNIH that endeavours to discover, develop, and seek regulatory approval for biological markers, known as biomarkers, to support new drug development, precision medicine, and medical diagnostics.

It said the Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.

The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit and advocacy organisations, the board explained.

Dr Carini had prior experience as a member of the FNIH Biomarkers Consortium Steering Committees, as well as having consulted and sat on many other distinguished international advisory boards and committees including the Medical Research Council, Innovative Medicine Initiative and the PML Consortium, it added.

“We are delighted that Claudio will be joining these prestigious biomarker committees,” said Oxford BioDynamics CEO Christian Hoyer Millar.

“The FNIH Biomarkers Consortium aims to accelerate the development of biomarker-based technologies, medicines, and therapies for the prevention, early detection, diagnosis, and treatment of disease, and this is a goal that is shared by Oxford BioDynamics.

“We believe that becoming a member of these important FNIH committees will be beneficial as we continue to progress towards our strategic aim of becoming the industry standard for epigenetic biomarker discovery.”

More news

28 Apr S&P reaffirms AA rating on UK, outlook clouded by Brexit

Standard&Poor's reaffirmed its rating on the United Kingdom's long-term sovereign debt but warned of the potential impact on the economy from the uncertainty around the Brexit negotiations and their eventual outcome.

28 Apr FX round-up: Sterling nonchalant after UK Q1 growth disappoints

Sterling made steady gains on most key cross on Friday, appearing nonchalant in its reaction to disappointing UK economic growth data out mid-morning.

28 Apr Europe close: Weak US, UK GDP weigh on shareson the continent

European stocks ended the day on a mixed note after weak readings on UK and US GDP dragged many indices into the red at the end of the month.

28 Apr Laird off to solid start, but second half remains key

Electronic component maker Laird reported strong sales growth in the first quarter of 2017 after a difficult year.

28 Apr General Motors truck and SUV sales drive record earnings

Growth at General Motors accelerated past analyst forecasts with a record first-quarter set of earnings.

28 Apr RBS and Lloyds Bank customers hit by online glitch on payday

Royal Bank of Scotland and Lloyds Banking Group customers were prevented from accessing money in their accounts due to a technical glitch ahead of the bank holiday weekend.

28 Apr Kennedy Wilson confirms quarterly dividend, new office leases

Kennedy Wilson Europe Real Estate announced it will pay an interim quarterly dividend of 12.0p per share, while also reporting strong leasing momentum across key investments in Greater London and Dublin.

28 Apr Time spins backwards on decision not to sell business

Time Inc stock reversed recent gains after the board decided not to sell the publishing business as it was being "reinvigorated" under a new strategy.

28 Apr Morgan Stanley downgrades Berendsen on competition concerns

Berendsen not only needs to invest in property, plant and equipment but is facing increasing competition in the UK, warned Morgan Stanley as it downgraded the stock on Friday.

28 Apr UK mortgages and consumer credit card borrowing both decline - BBA

Mortgage approvals and consumer credit card lending both fell in March according to fresh data from the banking industry, providing the reason for the fall in house prices announced elsewhere on Friday.